|
1
|
Ordás I, Eckmann L, Talamini M, Baumgart
DC and Sandborn WJ: Ulcerative colitis. Lancet. 380:1606–1619.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molodecky NA, Soon IS, Rabi DM, Ghali WA,
Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema
HW and Kaplan GG: Increasing incidence and prevalence of the
inflammatory bowel diseases with time, based on systematic review.
Gastroenterology. 142:46–54, e42; quiz e30. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jess T, Rungoe C and Peyrin-Biroulet L:
Risk of colorectal cancer in patients with ulcerative colitis: A
meta-analysis of population-based cohort studies. Clin
Gastroenterol Hepatol. 10:639–645. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eaden JA, Abrams KR and Mayberry JF: The
risk of colorectal cancer in ulcerative colitis: A meta-analysis.
Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Neovius M, Arkema EV, Blomqvist P, Ekbom A
and Smedby KE: Patients with ulcerative colitis miss more days of
work than the general population, even following colectomy.
Gastroenterology. 144:536–543. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khor B, Gardet A and Xavier RJ: Genetics
and pathogenesis of inflammatory bowel disease. Nature.
474:307–317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yashiro M: Ulcerative colitis-associated
colorectal cancer. World J Gastroenterol. 20:16389–16397. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ording AG, Horváth-Puhó E, Erichsen R,
Long MD, Baron JA, Lash TL and Sørensen HT: Five-year mortality in
colorectal cancer patients with ulcerative colitis or Crohn's
disease: A nationwide population-based cohort study. Inflamm Bowel
Dis. 19:800–805. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matsuoka H, Ikeuchi H, Uchino M, Bando T,
Takesue Y, Nishigami T and Tomita N: Clinicopathological features
of ulcerative colitis-associated colorectal cancer pointing to
efficiency of surveillance colonoscopy in a large retrospective
Japanese cohort. Int J Colorectal Dis. 28:829–834. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ullman T, Odze R and Farraye FA: Diagnosis
and management of dysplasia in patients with ulcerative colitis and
Crohn's disease of the colon. Inflamm Bowel Dis. 15:630–638. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dignass A, Eliakim R, Magro F, Maaser C,
Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire
S, et al: Second European evidence-based consensus on the diagnosis
and management of ulcerative colitis part 1: Definitions and
diagnosis. J Crohns Colitis. 6:965–990. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daperno M, Sostegni R, Rocca R, Rigazio C,
Scaglione N, Castellino F, Ercole E and Pera A: Review article:
Medical treatment of severe ulcerative colitis. Aliment Pharmacol
Ther. 16 Suppl 4:S7–S12. 2002. View Article : Google Scholar
|
|
13
|
Torres J, Boyapati RK, Kennedy NA, Louis
E, Colombel JF and Satsangi J: Systematic review of effects of
withdrawal of immunomodulators or biologic agents from patients
with inflammatory bowel disease. Gastroenterology. 149:1716–1730.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao HT, Peng J, Hu DD, Lin CY, Du B,
Tsang SW, Lin ZS, Zhang XJ, Lueng FP, Han QB and Bian ZX: Qing-dai
powder promotes recovery of colitis by inhibiting inflammatory
responses of colonic macrophages in dextran sulfate sodium-treated
mice. Chin Med. 10:292015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suzuki H, Kaneko T, Mizokami Y, Narasaka
T, Endo S, Matsui H, Yanaka A, Hirayama A and Hyodo I: Therapeutic
efficacy of the Qing Dai in patients with intractable ulcerative
colitis. World J Gastroenterol. 19:2718–2722. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin YK, See LC, Huang YH, Chang YC, Tsou
TC, Lin TY and Lin NL: Efficacy and safety of Indigo naturalis
extract in oil (Lindioil) in treating nail psoriasis: A randomized,
observer-blind, vehicle-controlled trial. Phytomedicine.
21:1015–1020. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee MY, Liu YW, Chen MH, Wu JY, Ho HY,
Wang QF and Chuang JJ: Indirubin-3′-monoxime promotes autophagic
and apoptotic death in JM1 human acute lymphoblastic leukemia cells
and K562 human chronic myelogenous leukemia cells. Oncol Rep.
29:2072–2078. 2013.PubMed/NCBI
|
|
18
|
Hao Y, Nagase K, Hori K, Wang S, Kogure Y,
Fukunaga K, Kashiwamura S, Yamamoto S, Nakamura S, Li J, et al:
Xilei san ameliorates experimental colitis in rats by selectively
degrading proinflammatory mediators and promoting mucosal repair.
Evid Based Complement Alternat Med. 2014:5695872014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hamamoto N, Maemura K, Hirata I, Murano M,
Sasaki S and Katsu K: Inhibition of dextran sulphate sodium
(DSS)-induced colitis in mice by intracolonically administered
antibodies against adhesion molecules (endothelial leucocyte
adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1
(ICAM-1)). Clin Exp Immunol. 117:462–468. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sasaki S, Hirata I, Maemura K, Hamamoto N,
Murano M, Toshina K and Katsu K: Prostaglandin E2 inhibits lesion
formation in dextran sodium sulphate-induced colitis in rats and
reduces the levels of mucosal inflammatory cytokines. Scand J
Immunol. 51:23–28. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dieleman LA, Palmen MJ, Akol H, Bloemena
E, Peña AS, Meuwissen SG and Van Rees EP: Chronic experimental
colitis induced by dextran sulphate sodium (DSS) is characterized
by Th1 and Th2 cytokines. Clin Exp Immunol. 114:385–391. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Laroui H, Ingersoll SA, Liu HC, Baker MT,
Ayyadurai S, Charania MA, Laroui F, Yan Y, Sitaraman SV and Merlin
D: Dextran sodium sulfate (DSS) induces colitis in mice by forming
nano-lipocomplexes with medium-chain-length fatty acids in the
colon. PLoS One. 7:e320842012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rashidian A, Mehrzadi S, Ghannadi AR,
Mahzooni P, Sadr S and Minaiyan M: Protective effect of ginger
volatile oil against acetic acid-induced colitis in rats: A light
microscopic evaluation. J Integr Med. 12:115–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bradley PP, Priebat DA, Christensen RD and
Rothstein G: Measurement of cutaneous inflammation: Estimation of
neutrophil content with an enzyme marker. J Invest Dermatol.
78:206–209. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vink EI, Yondola MA, Wu K and Hearing P:
Adenovirus E4-ORF3-dependent relocalization of TIF1α and TIF1γ
relies on access to the Coiled-Coil motif. Virology. 422:317–325.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gaifulina R, Maher AT, Kendall C, Nelson
J, Rodriguez-Justo M, Lau K and Thomas GM: Label-free Raman
spectroscopic imaging to extract morphological and chemical
information from a formalin-fixed, paraffin embedded rat colon
tissue section. Int J Exp Pathol. 97:337–350. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shen T, Gu D, Zhu Y, Shi J, Xu D and Cao
X: The value of eosinophil VCS parameters in predicting
hepatotoxicity of antituberculosis drugs. Int J Lab Hematol.
38:514–519. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yashiro M: Ulcerative colitis-associated
colorectal cancer. World J Gastroenterol. 20:16389–16397. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yarlas A, Yen L and Hodgkins P: The
relationship among multiple patient-reported outcomes measures for
patients with ulcerative colitis receiving treatment with MMX ®
formulated delayed-release mesalamine. Qual Life Res. 24:671–683.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Abraham BP: Cancer surveillance in
ulcerative colitis and Crohn's disease: New strategies. Curr Opin
Gastroenterol. 32:32–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Coskun M: Intestinal epithelium in
inflammatory bowel disease. Front Med (Lausanne).
1:242014.PubMed/NCBI
|
|
32
|
Akiho H, Yokoyama A, Abe S, Nakazono Y,
Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y and Ogino H:
Promising biological therapies for ulcerative colitis: A review of
the literature. World J Gastrointest Pathophysiol. 6:219–227. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Duerr RH, Taylor KD, Brant SR, Rioux JD,
Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M,
Griffiths A, et al: A genome-wide association study identifies
IL23R as an inflammatory bowel disease gene. Science.
314:1461–1463. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bianco AM, Girardelli M and Tommasini A:
Genetics of inflammatory bowel disease from multifactorial to
monogenic forms. World J Gastroenterol. 21:12296–12310. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
de Mattos BR, Garcia MP, Nogueira JB,
Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM
and Simioni PU: Inflammatory bowel disease: An overview of immune
mechanisms and biological treatments. Mediators Inflamm.
2015:4930122015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu ZJ, Yadav PK, Su JL, Wang JS and Fei
K: Potential role of Th17 cells in the pathogenesis of inflammatory
bowel disease. World J Gastroenterol. 15:5784–5788. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yamamoto-Furusho JK, Santiago-Hernández
JJ, Pérez-Hernández N, Ramírez-Fuentes S, Fragoso JM and
Vargas-Alarcón G: Interleukin 1 β (IL-1B) and IL-1 antagonist
receptor (IL-1RN) gene polymorphisms are associated with the
genetic susceptibility and steroid dependence in patients with
ulcerative colitis. J Clin Gastroenterol. 45:531–535. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Planell N, Lozano JJ, Mora-Buch R,
Masamunt MC, Jimeno M, Ordás I, Esteller M, Ricart E, Piqué JM,
Panés J and Salas A: Transcriptional analysis of the intestinal
mucosa of patients with ulcerative colitis in remission reveals
lasting epithelial cell alterations. Gut. 62:967–976. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Román J, Planell N, Lozano JJ, Aceituno M,
Esteller M, Pontes C, Balsa D, Merlos M, Panés J and Salas A:
Evaluation of responsive gene expression as a sensitive and
specific biomarker in patients with ulcerative colitis. Inflamm
Bowel Dis. 19:221–229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Andus T, Daig R, Vogl D, Aschenbrenner E,
Lock G, Hollerbach S, Köllinger M, Schölmerich J and Gross V:
Imbalance of the interleukin 1 system in colonic mucosa-association
with intestinal inflammation and interleukin 1 receptor antagonist
[corrected] genotype 2. Gut. 41:651–657. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Reinecker HC, Steffen M, Witthoeft T,
Pflueger I, Schreiber S, MacDermott RP and Raedler A: Enhanced
secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by
isolated lamina propria mononuclear cells from patients with
ulcerative colitis and Crohn's disease. Clin Exp Immunol.
94:174–181. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Heitz PU, Kasper M, van Noorden S, Polak
JM, Gregory H and Pearse AG: Immunohistochemical localisation of
urogastrone to human duodenal and submandibular glands. Gut.
19:408–413. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sinha A, Nightingale J, West KP,
Berlanga-Acosta J and Playford RJ: Epidermal growth factor enemas
with oral mesalamine for mild-to-moderate left-sided ulcerative
colitis or proctitis. N Engl J Med. 349:350–357. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brown GL, Nanney LB, Griffen J, Cramer AB,
Yancey JM, Curtsinger LJ III, Holtzin L, Schultz GS, Jurkiewicz MJ
and Lynch JB: Enhancement of wound healing by topical treatment
with epidermal growth factor. N Engl J Med. 321:76–79. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sullivan PB, Brueton MJ, Tabara ZB,
Goodlad RA, Lee CY and Wright NA: Epidermal growth factor in
necrotising enteritis. Lancet. 338:53–54. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kanazawa S, Tsunoda T, Onuma E, Majima T,
Kagiyama M and Kikuchi K: VEGF, basic-FGF, and TGF-beta in Crohn's
disease and ulcerative colitis: A novel mechanism of chronic
intestinal inflammation. Am J Gastroenterol. 96:822–828. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Frysz-Naglak D, Fryc B, Klimacka-Nawrot E,
Mazurek U, Suchecka W, Kajor M, Kurek J and Stadnicki A:
Expression, localization and systemic concentration of vascular
endothelial growth factor (VEGF) and its receptors in patients with
ulcerative colitis. Int Immunopharmacol. 11:220–225. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tolstanova G, Khomenko T, Deng X, Chen L,
Tarnawski A, Ahluwalia A, Szabo S and Sandor Z: Neutralizing
anti-vascular endothelial growth factor (VEGF) antibody reduces
severity of experimental ulcerative colitis in rats: Direct
evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther.
328:749–757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Al-Sadi R, Khatib K, Guo S, Ye D, Youssef
M and Ma T: Occludin regulates macromolecule flux across the
intestinal epithelial tight junction barrier. Am J Physiol
Gastrointest Liver Physiol. 300:G1054–G1064. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yamamoto-Furusho JK, Mendivil EJ and
Fonseca-Camarillo G: Differential expression of occludin in
patients with ulcerative colitis and healthy controls. Inflamm
Bowel Dis. 18:E19992012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nielsen OH, Verspaget HW and Elmgreen J:
Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by
sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment
Pharmacol Ther. 2:203–211. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kaiser GC, Yan F and Polk DB: Mesalamine
blocks tumor necrosis factor growth inhibition and nuclear factor
kappaB activation in mouse colonocytes. Gastroenterology.
116:602–609. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Caprilli R, Cesarini M, Angelucci E and
Frieri G: The long journey of salicylates in ulcerative colitis:
The past and the future. J Crohns Colitis. 3:149–156. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hanauer SB: Medical therapy of ulcerative
colitis. Lancet. 342:412–417. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gionchetti P, Rizzello F, Annese V,
Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M,
Danese S, Daperno M, et al: Use of corticosteroids and
immunosuppressive drugs in inflammatory bowel disease: Clinical
practice guidelines of the Italian Group for the Study of
Inflammatory Bowel Disease. Dig Liver Dis. pii:S1590–8658.
2017.
|
|
56
|
Podolsky DK: Inflammatory bowel disease. N
Engl J Med. 347:417–429. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wan P, Chen H, Guo Y and Bai AP: Advances
in treatment of ulcerative colitis with herbs: From bench to
bedside. World J Gastroenterol. 20:14099–14104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Guo M, Ding S, Zhao C, Gu X, He X, Huang
K, Luo Y, Liang Z, Tian H and Xu W: Red ginseng and semen coicis
can improve the structure of gut microbiota and relieve the
symptoms of ulcerative colitis. J Ethnopharmacol. 162:7–13. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Perse M and Cerar A: Dextran sodium
sulphate colitis mouse model: Traps and tricks. J Biomed
Biotechnol. 2012:7186172012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wiercinska-Drapalo A, Flisiak R,
Jaroszewicz J and Prokopowicz D: Plasma interleukin-18 reflects
severity of ulcerative colitis. World J Gastroenterol. 11:605–608.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Bersudsky M, Luski L, Fishman D, White RM,
Ziv-Sokolovskaya N, Dotan S, Rider P, Kaplanov I, Aychek T,
Dinarello CA, et al: Non-redundant properties of IL-1α and IL-1β
during acute colon inflammation in mice. Gut. 63:598–609. 2014.
View Article : Google Scholar : PubMed/NCBI
|
